Form 4 for IMNM Immunome Inc.
Accepted 2026-07-27 16:10:07 ET · period of report 2026-07-23 · accession 0001167496-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-27 16:10 | 2026-07-23 | IMNM | SIEGALL CLAY B | Pres, CEO, Dir | A - Grant | $0.00 | +180.0K | 870.7K | +26% | $0 |
| D | 2026-07-27 16:10 | 2026-07-23 | IMNM | SIEGALL CLAY B | Pres, CEO, Dir | A - Grant | $0.00 | +360.0K | 360.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-23 | A | A | 180,000 | $0.00 | 870,704 | D | — | — | (F1) Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2026-07-23 | A | A | 360,000 | $0.00 | 360,000 | D | $22.01 · — to 2036-07-22 | 360,000 Common Stock | (F2) 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date. |